Stocks in play: BriaCell Therapeutics Corp.

Announced that it has received approval from FDA on its pivotal registrational study design for Bria-IMT™ in combination with a checkpoint inhibitor in advanced metastatic breast cancer. FDA has approved the study design, the primary and secondary endpoints, and patient population in BriaCell’s upcoming pivotal registration clinical study. The study will include advanced metastatic breast cancer patients who have exhausted all other treatment options. BriaCell Therapeutics Corp. shares N.BCTX are trading up 37 cents at $6.51.

Read:

• Supply Shortage Could Drive Up Uranium Prices

• Novel Mechanisms Leading the Charge in Fight Against Cancer, Opening Door to New Drugs & Therapies

• Significant Oncology Results Set to be Delivered as Oral Presentations at ASCO 2023

• Promising New Cancer Treatment Data to Be Presented at 2023 ASCO Annual Meeting

• Global Lithium Supply Under Pressure as South American Nations Discuss "Lithium OPEC"